Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $306.11 | 12 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| EyePoint Pharmaceuticals US, Inc. | $92.60 | 4 | $0 (2022) |
| Genentech USA, Inc. | $72.80 | 3 | $0 (2021) |
| Bausch & Lomb Americas Inc. | $47.17 | 1 | $0 (2023) |
| Mallinckrodt LLC | $28.67 | 1 | $0 (2017) |
| Regeneron Healthcare Solutions, Inc. | $27.47 | 1 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $25.56 | 1 | $0 (2019) |
| TissueTech, Inc. | $11.84 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $74.64 | 2 | Bausch & Lomb Americas Inc. ($47.17) |
| 2022 | $69.38 | 3 | EyePoint Pharmaceuticals US, Inc. ($69.38) |
| 2021 | $46.52 | 2 | Genentech USA, Inc. ($23.30) |
| 2020 | $24.87 | 1 | Genentech USA, Inc. ($24.87) |
| 2019 | $50.19 | 2 | Novartis Pharmaceuticals Corporation ($25.56) |
| 2017 | $40.51 | 2 | Mallinckrodt LLC ($28.67) |
All Payment Transactions
12 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/10/2023 | Bausch & Lomb Americas Inc. | enVista MX60 IOL (Device) | Food and Beverage | In-kind items and services | $47.17 | General |
| Category: Ophthalmology | ||||||
| 09/22/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $27.47 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/19/2022 | EyePoint Pharmaceuticals US, Inc. | YUTIQ (Drug) | Food and Beverage | In-kind items and services | $24.08 | General |
| Category: Chronic Non-infectious Posterior Segment Uveitis | ||||||
| 05/11/2022 | EyePoint Pharmaceuticals US, Inc. | DEXYCU (Drug) | Food and Beverage | In-kind items and services | $23.63 | General |
| Category: Postoperative Inflammation | ||||||
| 01/31/2022 | EyePoint Pharmaceuticals US, Inc. | DEXYCU (Drug) | Food and Beverage | In-kind items and services | $21.67 | General |
| Category: Postoperative Inflammation | ||||||
| 11/22/2021 | EyePoint Pharmaceuticals US, Inc. | DEXYCU (Drug) | Food and Beverage | In-kind items and services | $23.22 | General |
| Category: Postoperative Inflammation | ||||||
| 02/04/2021 | Genentech USA, Inc. | Lucentis (Biological) | Food and Beverage | In-kind items and services | $23.30 | General |
| Category: Ophthalmology | ||||||
| 09/21/2020 | Genentech USA, Inc. | Lucentis (Biological) | Food and Beverage | In-kind items and services | $24.87 | General |
| Category: Ophthalmology | ||||||
| 07/24/2019 | Genentech USA, Inc. | Lucentis (Biological) | Food and Beverage | In-kind items and services | $24.63 | General |
| Category: Ophthalmology | ||||||
| 03/11/2019 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $25.56 | General |
| 04/10/2017 | TissueTech, Inc. | Prokera (Device), AmnioGraft, AmnioGuard | Food and Beverage | Cash or cash equivalent | $11.84 | General |
| Category: Medical Device (510K) | ||||||
| 03/22/2017 | Mallinckrodt LLC | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $28.67 | General |
| Category: AUTOIMMUNE AND RARE DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 3,811 | 16,179 | $12.9M | $2.2M |
| 2022 | 15 | 4,049 | 8,998 | $10.8M | $1.9M |
| 2021 | 13 | 3,447 | 7,611 | $7.5M | $1.4M |
| 2020 | 12 | 3,022 | 6,913 | $7.3M | $1.3M |
All Medicare Procedures & Services
55 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 214 | 2,122 | $9.5M | $1.5M | 15.3% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 25 | 7,680 | $844,800 | $215,300 | 25.5% |
| 67028 | Injection of drug into eye | Office | 2023 | 313 | 1,371 | $1.3M | $160,340 | 12.3% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 685 | 859 | $227,635 | $99,761 | 43.8% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 27 | 355 | $284,000 | $62,503 | 22.0% |
| 92134 | Imaging of retina | Office | 2023 | 914 | 1,482 | $296,400 | $55,064 | 18.6% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 109 | 419 | $83,800 | $29,701 | 35.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 238 | 252 | $55,440 | $23,499 | 42.4% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 743 | 1,053 | $105,300 | $22,977 | 21.8% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 135 | 135 | $46,575 | $18,043 | 38.7% |
| 92250 | Photography of the retina | Office | 2023 | 254 | 278 | $48,650 | $9,572 | 19.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 64 | 64 | $21,120 | $7,132 | 33.8% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 64 | 79 | $14,615 | $6,183 | 42.3% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 13 | 13 | $3,900 | $1,902 | 48.8% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 13 | 17 | $3,400 | $980.58 | 28.8% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 199 | 1,756 | $7.9M | $1.3M | 16.0% |
| 67028 | Injection of drug into eye | Office | 2022 | 417 | 1,488 | $1.4M | $172,911 | 12.5% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 38 | 690 | $552,000 | $153,922 | 27.9% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 735 | 995 | $263,675 | $108,522 | 41.2% |
| 92134 | Imaging of retina | Office | 2022 | 932 | 1,472 | $294,400 | $54,512 | 18.5% |
| J7999 | Compounded drug, not otherwise classified | Office | 2022 | 196 | 753 | $150,600 | $54,045 | 35.9% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 230 | 230 | $79,350 | $30,945 | 39.0% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2022 | 537 | 697 | $69,700 | $15,551 | 22.3% |
| 92012 | Established patient problem focused exam of visual system | Office | 2022 | 126 | 170 | $31,450 | $13,210 | 42.0% |
| 92250 | Photography of the retina | Office | 2022 | 248 | 280 | $49,000 | $9,276 | 18.9% |
About Dr. Anita Agarwal, MD
Dr. Anita Agarwal, MD is a Retina Specialist healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1508940628.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anita Agarwal, MD has received a total of $306.11 in payments from pharmaceutical and medical device companies, with $74.64 received in 2023. These payments were reported across 12 transactions from 7 companies. The most common payment nature is "Food and Beverage" ($306.11).
As a Medicare-enrolled provider, Agarwal has provided services to 14,329 Medicare beneficiaries, totaling 39,701 services with total Medicare billing of $6.8M. Data is available for 4 years (2020–2023), covering 55 distinct procedure/service records.
Practice Information
- Specialty Retina Specialist
- Other Specialties Ophthalmology, Ophthalmology
- Location San Francisco, CA
- Active Since 10/25/2006
- Last Updated 08/21/2020
- Taxonomy Code 207WX0107X
- Entity Type Individual
- NPI Number 1508940628
Products in Payments
- Lucentis (Biological) $72.80
- DEXYCU (Drug) $68.52
- enVista MX60 IOL (Device) $47.17
- ACTHAR (Biological) $28.67
- EYLEA HD (Biological) $27.47
- YUTIQ (Drug) $24.08
- Prokera (Device) $11.84
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Retina Specialist Doctors in San Francisco
Dr. Gaurav Shah, Md, MD
Retina Specialist — Payments: $762,639
Malini Pasricha, Md, MD
Retina Specialist — Payments: $12,732
Dr. Robert Kim, Md, MD
Retina Specialist — Payments: $5,432
Andrew Lin, Md, Ms, MD, MS
Retina Specialist — Payments: $1,658
Dr. Georgia Kamboj, Mbbs, Phd, MBBS, PHD
Retina Specialist — Payments: $850.21
Param Bhatter, Md, MD
Retina Specialist